BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for…
– BBP-711 led to near complete inhibition of glycolate oxidase throughout the dosing period and greater than 10-fold increases in plasma glycolate, suggesting it has the potential to be…